<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210389</url>
  </required_header>
  <id_info>
    <org_study_id>B2016-001-01</org_study_id>
    <nct_id>NCT03210389</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.</brief_title>
  <official_title>A Prospective, Single-arm, and Open Clinical Trial of Chemotherapy With Lobaplatin and 5-FU on Efficacy and Safety in Recurrent Local or Distant Advanced NPC.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of chemotherapy with
      Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years after chemotherapy</time_frame>
    <description>the time from randomization to death or disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after chemotherapy</time_frame>
    <description>the time from randomization to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years after chemotherapy</time_frame>
    <description>the ratio that patients who get PR or CR in all the patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>lobaplatin+5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobaplatin</intervention_name>
    <description>Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.</description>
    <arm_group_label>lobaplatin+5-FU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NPC diagnosed by pathology, with measurable lesions and imaging results, such as MRI
             and CT. Patients with no other lesions but bone metastasis are excluded.

          -  Recurrent locally or distant advanced NPC (rT3-4N0-3M0-1)

          -  ECOG 0 or 1

          -  Expected survival ≥ 1 year

          -  Without dysfunction of heart, lung, liver, kidney and hematopoiesis

          -  Patients are voluntary and signed informed consent

          -  No other anti-tumor treatment (including steroid)

        Exclusion Criteria:

          -  Allergy history to platinum

          -  Use of 5-FU in last 6 months

          -  Had major surgery in last 4 weeks, or the wound has not completely healed

          -  Toxicity from previous treatment is still ≥CTC AE grade 3

          -  History of other carcinoma in the past 5 years, except for treated carcinoma in situ
             of cervix, as well as basal cell carcinoma or squamous cell carcinoma of the skin

          -  Dysfunction of heart

          -  Bleeding ≥CTC AE grade 3

          -  Use of anticoagulant or vitamin K antagonists, except for small dose of aspirin and
             warfarin for prevention

          -  Patients participated in clinical trials of other drugs within last 4 weeks

          -  Mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun-fei Xia, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Sun Yat-Sen University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yun-fei Xia, Professor</last_name>
    <phone>86-13602805461</phone>
    <email>xiayf@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaohui Wang, MD</last_name>
    <phone>86-18826260661</phone>
    <email>wangxh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yun-fei Xia</investigator_full_name>
    <investigator_title>Director of Department of Radiation Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Recurrent Nasopharyngeal Carcinoma</keyword>
  <keyword>lobaptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

